Evidence map›Paper›PMID 33300085›Full record

ArticleMolecular medicine reports2021

miR‑139‑5p enhances cisplatin sensitivity in non‑small cell lung cancer cells by inhibiting cell proliferation and promoting apoptosis via the targeting of Homeobox protein Hox‑B2.

Hailian Du, Ya'nan Bao, Chunying Liu, Anqiao Zhong, Yikai Niu, Xingping Tang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Hailian Du *Department of Respiratory Medicine, Weifang Yidu Central Hospital, Weifang, Shandong 262500, P.R. China.
Ya'nan Bao *Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, P.R. China.
Chunying LiuUltrasonic Department, Anqiu People's Hospital, Anqiu, Shandong 262100, P.R. China.
Anqiao ZhongDepartment of Respiratory Medicine, Weifang Yidu Central Hospital, Weifang, Shandong 262500, P.R. China.
Yikai NiuDepartment of Respiratory Medicine, Weifang Yidu Central Hospital, Weifang, Shandong 262500, P.R. China.
Xingping TangDepartment of Respiratory Medicine, Weifang Yidu Central Hospital, Weifang, Shandong 262500, P.R. China.
Yidu Central Hospital of Weifang · CNKunming Medical University · CNZhangqiu City People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of chemotherapeutic dug resistance hinders the clinical treatment of cancer. MicroRNAs (miRNAs/miRs) have been revealed to serve essential roles in the drug resistance of numerous types of cancer. miR‑139‑5p was previously reported to be associated with cisplatin (DDP) sensitivity in human nasopharyngeal carcinoma cells and colorectal cancer cells. However, the effect and underlying mechanism of miR‑139‑5p in DDP sensitivity in non‑small cell lung cancer (NSCLC) cells has not yet been fully elucidated. In the present study, the expression of miR‑139‑5p and Homeobox protein Hox‑B2 (HOXB2) in NSCLC tissues was examined by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blotting. Subsequently, the effect of miR‑139‑5p on the DDP sensitivity of NSCLC cells

Indexed as

A549 CellsAgedApoptosisCarcinoma, Non-Small-Cell LungCell ProliferationCisplatinFemaleHomeodomain ProteinsHumansLung NeoplasmsMaleMicroRNAsMiddle AgedNeoplasm ProteinsRNA, NeoplasmTranscription FactorsCisplatinHomeodomain ProteinsHOXB2 protein, humanMicroRNAsMIRN139 microRNA, humanNeoplasm ProteinsRNA, NeoplasmTranscription Factorscisplatin sensitivitycleaved‑caspase‑3microRNA‑139‑5pnon‑small cell lung cancerPI3K/AKT

Identifiers

PMID33300085
PMCPMC7723155
OpenAlexW3110203687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.